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NSAID claim, 78% had a claim for a Cox-2, and individuals
with CV risk were more likely than those at lower risk to have
a Cox-2 claim (81% vs. 77%, p < 0.0001). As of December 31,
2004, 36% of continuing Cox-2 users had a pharmaceutical
marker suggesting signiﬁcant cardiovascular risk. CONCLU-
SION: As of December, 2004, most recent Cox-2 users with
ongoing prescription NSAID use continued using Cox-2s rather
than switching to nsNSAIDs, and individuals with cardiovascu-
lar risk were more likely than those at lower risk to continue
Cox-2 use. Subsequent analyses will continue to track utilization
in this cohort of recent Cox-2 users.
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THE IMPACT OF SPECIALTY CARE ON THE UTILIZATION OF
NEW DRUGS: THE CASE OF COX-2 SELECTIVE INHIBITORS
De Smet BD, Bernstein SJ, Fendrick AM, Stevenson JG
The University of Michigan Health System, Ann Arbor, MI, USA
OBJECTIVES: To compare the prescribing trends of traditional
and COX-2 selective NSAIDs by different physician specialties.
We also contrasted the appropriateness of NSAID medication
use between physician specialties by comparing prescribing data
to a clinically accepted therapeutic guideline on the appropriate
use of these medications. METHODS: We conducted a retro-
spective cohort study using pharmacy claims and clinical data on
43,936 adult patients enrolled with an IPA of a midwestern Uni-
versity-associated managed care plan. We identiﬁed continuously
enrolled managed care members who ﬁlled a new prescription
for NSAID or NSAID combination from 1999–2002 on a
chronic-use basis. RESULTS: In total, 1576 patients were started
on a traditional NSAID or a COX-2 inhibitor. Primary care
patients were younger and less likely to have comorbid condi-
tions. Overall, COX-2 use was two times greater among patients
seen by specialists compared to patients seen by PCPs. Use and
appropriateness patterns between the specialties were similar
over the time course of the analysis. Multivariate logistic regres-
sion showed that history of rheumatoid arthritis, osteoarthritis,
generalized musculoskeletal pain, or a serious gastrointestinal
complication were associated with increased likelihood of being
prescribed a COX-2 inhibitor and being placed on therapy con-
sidered inappropriate. History of coronary artery disease and
patient age were associated with an increased risk of receiving
inappropriate therapy. CONCLUSION: In addition to prescrib-
ing COX-2 inhibitors at twice the rate of PCPs, specialists were
less compliant with appropriate use guidelines that considered
comorbidities. Overall compliance with appropriate use guide-
lines was 62%, with PCPs 67% and specialists 49%. Using this
drug class as a model for physician adoption of new therapeutic
agents, specialists were observed to be more likely to use new
drugs, despite the lack of clinical scenarios supporting their 
use over traditional therapies. Education and interventions to
promote appropriate prescribing should target both PCPs and
specialists.
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OBJECTIVES: Several checklists have been proposed for assess-
ing the methodological quality of economic evaluations.
However, there is limited literature on the use of such checklists.
The purpose of this study was to assess the feasibility and relia-
bility of a well-known checklist as a quality assessment tool.
METHODS: Five experienced health economists applied the
BMJ checklist, a 35-item questionnaire, to 12 model-based eco-
nomic evaluations of cyclooxygenase-2 (COX-2) inhibitors.
Overall quality of the studies was assessed by measuring the
number of positive answers to the questions. RESULTS: The ﬁve
assessors were able to apply the checklist to all 12 studies. The
checklist was able to discriminate among the 12 studies, with the
total number of positive answers per study ranging from 87 to
132. Although there was a high level of agreement among the
assessors’ overall scores for the 12 studies, there was consider-
able disagreement on speciﬁc questions, with 100% agreement
among all 5 assessors in only 168/420 (35 ¥ 12) possible
instances. Often, disagreements occurred for seemingly factual
questions (example: Are details of currency or price adjustments
for inﬂation or currency conversion given?). Also, there was a
strong relationship between the overall study quality score of the
studies and the level of agreement among the assessors. This
reﬂected the fact that quality of study reporting is the main focus
of the BMJ checklist, rather than the underlying methodological
quality of the studies. Even given this focus, it was felt that addi-
tional questions related to drug dosing and cost as well as main
model parameters should be added to the checklist. CONCLU-
SIONS: The checklist could discriminate among studies, but
focussed mainly on the quality of reporting rather than the
methodological quality of studies. More study is required of the
purpose, feasibility, and reliability of the various methodological
checklists.
ARTHRITIS—Other
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OBJECTIVE: To characterize the burden of illness of ﬁbromyal-
gia to employers, insurers, and society. METHODS: Two data-
bases were searched, Medline and Healthstar, limited to English
language and years 1990–2004. Key search words included
ﬁbromyalgia, cost, economics, employment, productivity and
disability. Articles were selected that reported utilization of
health care resources characterized by either indirect or direct
costs. The total cost of ﬁbromyalgia and contributing cost 
drivers were determined; costs were compared to other diseases.
RESULTS: A total of 12 articles were reviewed for cost and 
ﬁve of these reported productivity cost. The estimated annual
total cost per patient was $5163–$11,548 for employers,
$2274–$9374 for insurers and $3534.84 for society. Direct costs
included: inpatient, outpatient, ofﬁce visits, medications, alter-
native medicine, diagnostic tests, lab work and emergency room
visits. Indirect costs included: absenteeism, presenteeism, work
loss and disability. Productivity loss, medical care and prescrip-
tions were the major determinants of costs to employers. Insurer
costs were driven by inpatient care, medications and outpatient
visits. Societal costs were driven by health care procedures and
productivity impairments. Productivity costs were accountable
for 26%–54% of the total cost to employers, and were most
often measured by disability and time off work. Only one
abstract was identiﬁed that measured productivity in FMS
patients using a patient-reported measure. CONCLUSION:
Fibromyalgia is a costly condition; with cost drivers varying by
payor type. Productivity is a signiﬁcant cost driver that should
be considered to capture the full burden of ﬁbromyalgia to both
the employer and society. Most studies assessing productivity
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only addressed absenteeism ± disability without regards to 
presenteeism; true productivity costs are likely even higher 
than reported. Cost assessment measures in clinical trials for
ﬁbromyalgia need to be determined.
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OBJECTIVE: To develop benchmark methodology for identify-
ing gout patients and acute attacks, prevalence, patient charac-
teristics, and rate of gout attacks from MCO data. METHODS:
This retrospective study was in a 1.1 million southeastern US
MCO. Patients had ≥2 visits with ICD-9 code for gout (274.xx)
or ≥1 pharmacy script(s) for allopurinol, colchicine, probenecid,
or sulﬁnpyrazone between January 1, 2000 and December 31,
2002 (intake period). Patients on allopurinol without an ICD-9
code for gout were excluded if they had neoplasm or nephrolithi-
asis. First gout claim/script within the intake period was the
index date. Patients ≥18 years with continuous eligibility for one-
year pre and post index date were included. Gout attack was
deﬁned as ofﬁce or ER visit with medical claim for gout or joint
pain (ICD-9 719.4x) and ≥1 of the following within seven days
but not within six months prior: new pharmacy claim for
NSAID, colchicine, corticosteroid, ACTH, intra-articular aspi-
ration/injection, or microscopy of joint ﬂuid. Statistical analysis
was performed on continuous and categorical variables.
RESULTS: A study cohort of 5942 gout patients was identiﬁed
with prevalence rate of 1.6%. In this database, gout patients
were relatively older (mean age 57 ± 14 years), predominantly
male (76%), suffered from substantial cardiovascular pre-index
comorbidities (hypertension [40%], CHD [25%]), diabetes
(18%), and renal impairment (5%). Nineteen percent (1121/
5942) of patients had ≥1 gout attack. Among the gout attack
subset, median rate of attacks per patient per year was 0.57
(range 0.24 to 6.9). CONCLUSION: Patients with gout were
older, predominantly male, and had high rates of cardiovascular
comorbidities. The prevalence rate identiﬁed is similar to other
estimates in the literature. Further research is necessary to reﬁne
and validate our methodology since this work did not address
self-managed gout attacks.
ARTHRITIS—Rheumatoid Arthritis
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OBJECTIVES: To compare health care utilization and total
direct medical cost in patients with Rheumatoid arthritis (RA)
with those of the general population in a Hospital based Health
Management Organization (HMO). METHODS: A toal of 
127 RA patients (all fulﬁlling ARA criteria 1982) (111 (87%)
females, mean age 62.7 years, median disease duration: 6.7
(interquartile range: 4–11), 77% seropositive) with continuous
afﬁliation with the HMO during year 2003 were included. All
direct medical expenditures from the insurer’s point of view and
health care utilization during year 2003 were considered and
compared with mean values of the adult HMO population 
(n = 69,891), standardized by patient’s sex and age distribution.
Data was obtained from charges to the HMO and considered as
proxy to costs. Costs are expressed in 2003 American dollars.
RESULTS: RA had signiﬁcantly more mean annual hospitaliza-
tions: 0.27 (SD0 .61) vs. 0.16 (SD 0.51), p = 0.025; mean annual
medications purchased :34 (SD27) vs. 27.5 (SD 27) p = 0.01;
mean annual medical visits 19 (SD11) vs. 14.5 (SD 14) p < 0.001,
and outpatients procedures 48 (SD37) vs. 31 (SD 25); p < 0.001.
RA patients also had signiﬁcantly more mean total direct medical
costs than general population ($752 vs. $557; p = 0.006). Com-
ponents of direct medical costs were: medical visits: 13%, med-
ications: 24%, hospitalizations: 38% and outpatient procedures:
25%. Only one patient was on biologic treatment. There were
no differences in costs between seropositive and seronegative
patients, males or females or in relation to disease duration.
CONCLUSIONS: RA patients used signiﬁcantly more health
care resources and were signiﬁcantly more costly than the general
population of same age and sex. In a developing country with
scarce use of biologic therapy, direct medical costs are still mainly
driven by hospitalizations.
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OBJECTIVES: To determine rheumatologists’ current prescrib-
ing practices, laboratory monitoring protocols, and perceived
barriers to prescribing Tumor Necrosis Factor (TNF) inhibitors
(adalimumab, etanercept, and inﬂiximab) in patients with
rheumatoid arthritis (RA). METHODS: A survey questionnaire
was mailed to 1970 rheumatologists who were randomly
selected from a national sample of 3007 rheumatologists. A 
one-page nonresponse questionnaire was mailed to about 200
randomly selected nonresponding rheumatologists to assess non-
response bias. RESULTS: Two mailings yielded a response rate
of 22.2% (428 completed, usable surveys out of 1925 deliver-
able surveys). Rheumatologists reported using all three agents in
patients with moderate RA (82–87%) and severe RA (94–96%).
Also, some rheumatologists (10–18%) reported using these
agents in newly diagnosed and mild RA patients. Sixty eight
percent preferred etanercept as ﬁrst choice TNF inhibitor while
28.5% and 20.3% preferred adalimumab and inﬂiximab as ﬁrst
choice TNF inhibitors, respectively. In patients with severe RA
and an inadequate response to methotrexate, 91% rheumatolo-
gists reported using TNF inhibitor with one other disease mod-
ifying anti-rheumatic drug (DMARD) and 27.9% reported using
TNF inhibitor with two other DMARDs. Over 94% rheuma-
tologists stated switching patients from one TNF inhibitor to 
a different TNF inhibitor due to inadequate response or side
effects. Most rheumatologists ordered puriﬁed protein derivative
test (96%) when administering these agents with almost 82%
conducting this test at baseline. Other tests ordered were com-
plete blood count, chest radiography, antinuclear antibody, and
creatinine during baseline and follow-up of patients. Costs to the
patients and insurance coverage were perceived as major barri-
ers to prescribing these agents although the perception was a
little lower with inﬂiximab than with adalimumab or etanercept.
CONCLUSIONS: Rheumatologists are fairly similar in their use
of the three different TNF inhibitors although some variation
